Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice

World Health Organization Global HIV/AIDS response - epidemic update and health sector progress towards universal access: Progress report 2011. Available online:http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf.

Chun, 1997, Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy, Proc. Natl. Acad. Sci. U S A, 94, 13193, 10.1073/pnas.94.24.13193

Finzi, 1999, Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy, Nat. Med., 5, 512, 10.1038/8394

Finzi, 1997, Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy, Science, 278, 1295, 10.1126/science.278.5341.1295

Wong, 1997, Recovery of replication-competent HIV despite prolonged suppression of plasma viremia, Science, 278, 1291, 10.1126/science.278.5341.1291

Calza, 2012, Renal toxicity associated with antiretroviral therapy, HIV Clin. Trials, 13, 189, 10.1310/hct1304-189

Domingo, 2012, Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy, AIDS Rev., 14, 112

Hester, 2012, HIV medications: An update and review of metabolic complications, Nutr. Clin. Pract., 27, 51, 10.1177/0884533611431985

Jones, 2012, Liver toxicity of antiretroviral drugs, Semin. Liver Dis., 32, 167, 10.1055/s-0032-1316472

Lipshultz, 2012, HAART to heart: Highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults, Expert Rev. Anti-Infect. Ther., 10, 661, 10.1586/eri.12.53

Hutter, 2009, Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation, N. Engl. J. Med., 360, 692, 10.1056/NEJMoa0802905

Allers, 2011, Evidence for the cure of HIV infection by CCR5delta32/delta32 stem cell transplantation, Blood, 117, 2791, 10.1182/blood-2010-09-309591

Yukl, 2013, Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient, PLoS Pathog., 9, e1003347, 10.1371/journal.ppat.1003347

Henrich, 2013, Long-term reduction in peripheral blood HIV-1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation, J. Infect. Dis., 207, 1694, 10.1093/infdis/jit086

Hutter, 2011, Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: The experiences of more than 25 years, Clin. Exp. Immunol., 163, 284, 10.1111/j.1365-2249.2010.04312.x

Burnett, 2012, Creating genetic resistance to HIV, Curr. Opin. Immunol., 24, 625, 10.1016/j.coi.2012.08.013

Holt, 2010, Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo, Nat. Biotechnol., 28, 839, 10.1038/nbt.1663

Hur, 2012, Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice, Blood, 120, 4571, 10.1182/blood-2012-04-422303

Joseph, 2010, Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody, J. Virol., 84, 6645, 10.1128/JVI.02339-09

Ringpis, 2012, Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice, PLoS One, 7, e53492, 10.1371/journal.pone.0053492

Vatakis, D.N., Bristol, G.C., Kim, S.G., Levin, B., Liu, W., Radu, C.G., Kitchen, S.G., and Zack, J.A. (2012). Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J. Vis. Exp., e4181.

Kohn, 1999, A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children, Blood, 94, 368, 10.1182/blood.V94.1.368.413a47_368_371

Podsakoff, 2005, Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells, Mol. Ther., 12, 77, 10.1016/j.ymthe.2005.02.024

Amado, 2004, Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: Myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients, Hum. Gene Ther., 15, 251, 10.1089/104303404322886101

Mitsuyasu, 2009, Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells, Nat. Med., 15, 285, 10.1038/nm.1932

DiGiusto, 2010, RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma, Sci. Transl. Med., 2, 1, 10.1126/scitranslmed.3000931

Li, 2005, Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy, Mol. Ther., 12, 900, 10.1016/j.ymthe.2005.07.524

Ustek, 2012, A genome-wide analysis of lentivector integration sites using targeted sequence capture and next generation sequencing technology, Infect. Genet. Evol., 12, 1349, 10.1016/j.meegid.2012.05.001

An, 2006, Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors, Mol. Ther., 14, 494, 10.1016/j.ymthe.2006.05.015

Chung, 2012, Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy, Hum. Gene Ther., 23, 1200, 10.1089/hum.2012.011

Davis, 1999, Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: Implications for drug resistance gene therapy, Hum. Gene Ther., 10, 2769, 10.1089/10430349950016500

Beard, 2010, Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates, J. Clin. Invest., 120, 2345, 10.1172/JCI40767

Chinnasamy, 2004, Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide, Hum. Gene Ther., 15, 758, 10.1089/1043034041648417

Gori, 2012, In vivo selection of autologous mgmt gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model, Cancer Gene Ther., 19, 523, 10.1038/cgt.2012.25

Jansen, 2002, Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells, Cancer Gene Ther., 9, 737, 10.1038/sj.cgt.7700490

Neff, 2005, Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy, Blood, 105, 997, 10.1182/blood-2004-08-3169

Younan, 2013, Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model, Blood, 122, 179, 10.1182/blood-2013-01-482224

Food and Drug Administration Structured approach to benefit-risk assessment in drug regulatory decision-making. Available online:http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf.

Coplan, 2011, Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines, Clin. Pharmacol. Ther., 89, 312, 10.1038/clpt.2010.291

Food and Drug Administration Public meeting on HIV patient-focused drug development and HIV cure research. Available online:http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm348598.htm.

National Institutes of Health AIDSinfo. Available online:http://aidsinfo.nih.gov/guidelines.

Lewden, 2007, HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population, J. Acquir. Immune Defic. Syndr., 46, 72, 10.1097/QAI.0b013e318134257a

Engsig, 2010, Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study, BMC Infect. Dis., 10, 318, 10.1186/1471-2334-10-318

Gaardbo, 2012, Incomplete immune recovery in HIV infection: Mechanisms, relevance for clinical care, and possible solutions, Clin. Dev. Immunol., 2012, 670957, 10.1155/2012/670957

Piketty, 2001, Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen, J. Infect. Dis., 183, 1328, 10.1086/319861

Re, 2013, Stem cell mobilization in HIV seropositive patients with lymphoma, Haematologica, 98, 1762, 10.3324/haematol.2013.089052

Krishnan, 2000, Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors, Blood, 95, 1588, 10.1182/blood.V95.5.1588.005k38_1588_1593

Agarwal, 2010, High incidence of zidovudine induced anaemia in HIV infected patients in Eastern India, Indian J. Med. Res., 132, 386

Costantini, 2006, Impaired in-vitro growth of megakaryocytic colonies derived from CD34 cells of HIV-1-infected patients with active viral replication, AIDS, 20, 1713, 10.1097/01.aids.0000242817.88086.8c

Isgro, 2008, Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART, Clin. Infect. Dis., 46, 1902, 10.1086/588480

Thiebot, 2001, Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection, J. Virol., 75, 11594, 10.1128/JVI.75.23.11594-11602.2001

Costantini, 2009, Abnormalities of erythropoiesis during HIV-1 disease: A longitudinal analysis, J. Acquir. Immune Defic. Syndr., 52, 70, 10.1097/QAI.0b013e3181af65c5

Costantini, 2010, HIV-induced abnormalities in myelopoiesis and their recovery following antiretroviral therapy, Curr. HIV Res., 8, 336, 10.2174/157016210791208604

Sauce, 2011, HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis, Blood, 117, 5142, 10.1182/blood-2011-01-331306

Krishnan, 2009, HIV-infected patients, Biol. Blood Marrow Transplant, 15, 142, 10.1016/j.bbmt.2008.10.002

Krishnan, 2005, Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas, Blood, 105, 874, 10.1182/blood-2004-04-1532

Schooley, 2000, Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease, J. Infect. Dis., 181, 148, 10.1086/315168

Keating, 2011, Plerixafor: A review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma, Drugs, 71, 1623, 10.2165/11206040-000000000-00000

McNamara, 2012, Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-kappaB activation, J. Virol., 86, 9337, 10.1128/JVI.00895-12

Nixon, 2013, HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice, Blood, 122, 2195, 10.1182/blood-2013-04-496950

McNamara, 2010, Towards a cure for HIV: The identification and characterization of HIV reservoirs in optimally treated people, Cell Res., 20, 1185, 10.1038/cr.2010.140

Eisele, 2012, Redefining the viral reservoirs that prevent HIV-1 eradication, Immunity, 37, 377, 10.1016/j.immuni.2012.08.010

McNamara, 2013, CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression, J. Infect. Dis., 207, 1807, 10.1093/infdis/jit118

Sachdeva, 2010, Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients, J. Acquir. Immune. Defic. Syndr., 54, 447, 10.1097/QAI.0b013e3181e0c7d0

Biffi, 2013, Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy, Science, 341, 1233158, 10.1126/science.1233158

Aiuti, 2013, Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome, Science, 341, 1233151, 10.1126/science.1233151

Candotti, 2012, Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: Clinical comparison of retroviral vectors and treatment plans, Blood, 120, 3635, 10.1182/blood-2012-02-400937

Manzano, 2007, Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: Results of a multicenter study, Bone Marrow Transplant., 40, 535, 10.1038/sj.bmt.1705769

Slavin, 1998, Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756

Aiuti, 2009, Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N. Engl. J. Med., 360, 447, 10.1056/NEJMoa0805817

Aiuti, 2002, Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning, Science, 296, 2410, 10.1126/science.1070104

Kang, 2010, Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils, Blood, 115, 783, 10.1182/blood-2009-05-222760

Kang, 2011, Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial, Mol. Ther., 19, 2092, 10.1038/mt.2011.166

Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat. Med., 12, 401, 10.1038/nm1393

Lafeuillade, 2011, Potential strategies for an HIV infection cure, HIV Clin. Trials, 12, 121, 10.1310/hct1203-121

Kiem, 2012, Hematopoietic-stem-cell-based gene therapy for HIV disease, Cell Stem Cell, 10, 137, 10.1016/j.stem.2011.12.015

Khera, 2012, Economics of hematopoietic cell transplantation, Blood, 120, 1545, 10.1182/blood-2012-05-426783

Sloan, 2012, Newer drugs and earlier treatment: Impact on lifetime cost of care for HIV-infected adults, AIDS, 26, 45, 10.1097/QAD.0b013e32834dce6e

Walensky, 2013, Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States, Ann. Intern Med., 158, 84, 10.7326/0003-4819-158-2-201301150-00002

Gabriel, 2009, Comprehensive genomic access to vector integration in clinical gene therapy, Nat. Med., 15, 1431, 10.1038/nm.2057

Drmanac, 2001, DNA sequencing by hybridization with arrays of samples or probes, Methods Mol. Biol., 170, 173